Maintenance fees coming due
9 maintenance fees come due in the 12 months from Nov 20, 2026, the next on Dec 20, 2026. Unpaid by Jun 21, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,680,051 | Crystalline Forms of 3-Substituted 1,2,4- Oxadiazole In force Fee due Dec 20, 2026 Lapses if unpaid Jun 21, 2027 · High confidence | Aurigene Oncology Limited | In force | Dec 20, 2026 | Jun 21, 2027 | High confidence | |
| US 11,691,987 | Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors In force Fee due Jan 4, 2027 Lapses if unpaid Jul 6, 2027 · Medium confidence | Aurigene Oncology Limited | In force | Jan 4, 2027 | Jul 6, 2027 | Medium confidence | |
| US 10,391,082 | Protein Kinase Inhibitors In force Fee due Feb 27, 2027 Lapses if unpaid Aug 27, 2027 · Low confidence | Aurigene Oncology Limited | In force | Feb 27, 2027 | Aug 27, 2027 | Low confidence | |
| US 11,865,114 | Method for Treating Diseases Using SMARCA2/4 Degraders In force Fee due Jul 9, 2027 Lapses if unpaid Jan 10, 2028 · High confidence | Aurigene Oncology Limited | In force | Jul 9, 2027 | Jan 10, 2028 | High confidence | |
| US 11,866,420 | Novel Hydrochloride Salt Forms of a Sulfonamide Structured Kinase Inhibitor In force Fee due Jul 9, 2027 Lapses if unpaid Jan 10, 2028 · High confidence | Aurigene Oncology Limited | In force | Jul 9, 2027 | Jan 10, 2028 | High confidence | |
| US 10,590,093 | 1,2,4-Oxadiazole Derivatives as Immunomodulators In force Fee due Sep 17, 2027 Lapses if unpaid Mar 17, 2028 · High confidence | Aurigene Oncology Limited | In force | Sep 17, 2027 | Mar 17, 2028 | High confidence | |
| US 10,590,118 | Bicyclic Heterocyclic Derivatives as Bromodomain Inhibitors In force Fee due Sep 17, 2027 Lapses if unpaid Mar 17, 2028 · High confidence | Aurigene Oncology Limited | In force | Sep 17, 2027 | Mar 17, 2028 | High confidence | |
| US 10,640,517 | Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors In force Fee due Nov 5, 2027 Lapses if unpaid May 5, 2028 · High confidence | Aurigene Oncology Limited | In force | Nov 5, 2027 | May 5, 2028 | High confidence | |
| US 11,981,685 | Bicyclic Heterocyclyl Derivatives as IRAK4 Inhibitors In force Fee due Nov 14, 2027 Lapses if unpaid May 15, 2028 · Medium confidence | Aurigene Oncology Limited | In force | Nov 14, 2027 | May 15, 2028 | Medium confidence |
9 of 9 patents shown. Soonest fee due date first, then patent number.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.